ArticleNature communications2023
Mitochondrial ATP synthase as a direct molecular target of chromium(III) to ameliorate hyperglycaemia stress.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Chromium(III) Beyond Insulin: A Mechanistic Roadmap Across the Energy-Redox-Inflammation Triad in Obesity and Cardiometabolic Disease.Biological trace element research · 2026Review
- Potentially Toxic Elements-mediated Toxicity on Vagus Nerve and Cellular Energy Expenditure in Noncommunicable Diseases: A Systematic Review and Evidence Map.Biological trace element research · 2026Review
- Chromium propionate enhanced the production performance of yellow-feathered broilers under chronic heat stress exposure by improving intestinal health.Stress biology · 2026Article
- The arsenic proteome in cancer: Unravelling molecular mechanisms of anticancer drugs.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026Review
- Dietary chromium picolinate-promoted oxidative phosphorylation may be a potential mean to improve hypoxia tolerance of juvenile grass carp (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Resveratrol as a Potential Platelet Inhibitor in Aspirin-Resistant Diabetic Patients-A Novel Therapeutic Strategy Targeting FLife (Basel, Switzerland) · 2025Review
- CysMP reveals metal ion-specific metalloproteomes and copper-regulated PGK1 activity in glycolysis.Science advances · 2025Article
- An Overview of Hexavalent Chromium-Induced Necroptosis, Pyroptosis, and Ferroptosis.Biological trace element research · 2025Review
- Review
- TIMP1 regulates ferroptosis in osteoblasts by inhibiting TFRC ubiquitination: an in vitro and in vivo study.Molecular medicine (Cambridge, Mass.) · 2024Article
- Metal-detection based techniques and their applications in metallobiology.Chemical science · 2024Review
- Understanding Cr(III) Action on Mitochondrial ATP Synthase and AMPK Efficacy: Insights from Previous Studies-a Review.Biological trace element research · 2024Review
- Targeting Mitochondrial ATP-Synthase: Evolving Role of Chromium as a Regulator of Carbohydrate and Fat Metabolism.Biological trace element research · 2024Review
- Editorial.Biological trace element research · 2024Article
- Recent Advances in Metalloproteomics.Biomolecules · 2024Review
- Impact of Chromium Picolinate on Leydig Cell Steroidogenesis and Antioxidant Balance Using an In Vitro Insulin Resistance Model.Antioxidants (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromium(III) is extensively used as a supplement for muscle development and the treatment of diabetes mellitus. However, its mode of action, essentiality, and physiological/pharmacological effects have been a subject of scientific debate for over half a century owing to the failure in identifying the molecular targets of Cr(III). Herein, by integrating fluorescence imaging with a proteomic approach, we visualized the Cr(III) proteome being mainly localized in the mitochondria, and subsequently identified and validated eight Cr(III)-binding proteins, which are predominately associated with ATP synthesis. We show that Cr(III) binds to ATP synthase at its beta subunit via the catalytic residues of Thr213/Glu242 and the nucleotide in the active site. Such a binding suppresses ATP synthase activity, leading to the activation of AMPK, improving glucose metabolism, and rescuing mitochondria from hyperglycaemia-induced fragmentation. The mode of action of Cr(III) in cells also holds true in type II diabetic male mice. Through this study, we resolve the long-standing question of how Cr(III) ameliorates hyperglycaemia stress at the molecular level, opening a new horizon for further exploration of the pharmacological effects of Cr(III).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.